Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
For example, in the case of mitochondrial fusion, the overexpression of Fzo1A/B or MFN1/2 prevents excessive fragmentation of mitochondria
What they did: They transected the quadriceps (front thigh) of rats and divided them into three groups: Control, no drugs Dexamethasone, a potent corticosteroid that is known to impair healing Dexamethasone + BPC-157 What they found: Dexamethasone group: 50 % worse healing than control (confirmed negative effect of steroids) Dexamethasone + BPC-157 group: healing at the level of controls without steroids Why it matters: This is a highly clinically relevant finding
These medicines also help regulate blood sugar by increasing insulin release
Both are available at Peptides Costa Rica GLOW starts from $120 per vial.
It also speculated that the p38 MAPK pathway might be involved in the downregulation of microRNA (miR-339-5p) [9]
